Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Margetuximab: Short Chapter

No authors listed
In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
.
Free Books & Documents
Review

Margetuximab: Short Chapter

No authors listed.
Free Books & Documents

Excerpt

Margetuximab is a monoclonal antibody to HER2 used in combination with chemotherapy for treatment of adults with advanced, relapsed or refractory HER2-positive breast cancer. Margetuximab therapy is associated with transient serum aminotransferase elevations during therapy in as many as one-third of patients but has not been linked to instances of clinically apparent liver injury.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. FDA. Integrated Review. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761150Orig1s000M...(FDA summary data on the safety and efficacy of margetuximab, submitted in support of the application for approval as therapy of metastatic HER2 positive breast cancer).
    1. Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, et al.; SOPHIA Study Group. Efficacy of margetuximab vs tastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:573-584. - PMC - PubMed
    1. Markham A. Margetuximab: first approval. Drugs. 2021;81:599-604. - PubMed
    1. Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17:594-604. - PubMed
    1. Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, Shetty KA, et al. FDA Approval summary: margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2022;28:1487-1492. - PMC - PubMed

LinkOut - more resources